TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11341128

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 9136820

Group type: EXPERIMENTAL
Intervention: Cure of Helicobacter pylori infection
Number of subjects: 460

Group type: COMPARATOR
Intervention: Persisting Helicobacter pylori infection
Number of subjects: 460
Study: 8489087

Group type: EXPERIMENTAL
Intervention: Gentamicin admixed with clindamycin 900 mg IVPB every 8 hours (Group I n = 80)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Gentamicin IVPB q8h plus clindamycin 600 mg IVPB every 6 hours (Group II n = 46)
Number of subjects: 126
Study: 3328790

Group type: EXPERIMENTAL
Intervention: Hexabrix 160 (H 16)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sodium Meglumine diatrizoate (R 76)
Number of subjects: 20
Study: 2674460

Group type: EXPERIMENTAL
Intervention: 60 mg of cisplatin (CDDP)/m2
Number of subjects: 103

Group type: COMPARATOR
Intervention: 150 mg of carboplatin (CBDCA)/m2
Number of subjects: 103
Study: 31122824

Group type: EXPERIMENTAL
Intervention: Protocol C (Moviprep® after capsule arrival)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Protocol A (Clear liquids diet + fasting)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Protocol B (Protocol A + Moviprep® before examination)
Number of subjects: 101
Study: 28735826

Group type: EXPERIMENTAL
Intervention: affron® 28mg/day
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: affron® 22mg/day
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 25934131

Group type: EXPERIMENTAL
Intervention: 1320 mg/day of EPA and 880 mg/day of DHA
Number of subjects: 82

Group type: COMPARATOR
Intervention: Olive oil placebo
Number of subjects: 82
Study: 23438159

Group type: EXPERIMENTAL
Intervention: Paliperidone (PAL)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 27
Study: 21962261

Group type: EXPERIMENTAL
Intervention: cTnI at 1 hour
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: cTnI at 24 hours
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: CK‐MB at 24 hours
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Interleukin 6 at 1 hour
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor‐α at 1 hour
Number of subjects: 28
Study: 19101265

Group type: EXPERIMENTAL
Intervention: rSo(2) desaturation score greater than 3,000%‐second
Number of subjects: 0
Study: 17050790

Group type: EXPERIMENTAL
Intervention: Entecavir 0.1 mg once daily for 14 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg once daily for 14 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Entecavir 1 mg once daily for 14 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Matched placebo once daily for 14 days
Number of subjects: 24
Study: 15327932

Group type: EXPERIMENTAL
Intervention: Social attention allocation using eye gaze cues
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Symbolic cues (words) for attention allocation
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Automatic allocation of attention
Number of subjects: 1
Study: 10906619

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Estrogen
Number of subjects: 0
Study: 9565715

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8401679

Group type: EXPERIMENTAL
Intervention: Systen
Number of subjects: 104

Group type: COMPARATOR
Intervention: Estraderm
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study: 2877955

Group type: EXPERIMENTAL
Intervention: Procaterol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 12
Study: 31853864

Group type: EXPERIMENTAL
Intervention: Bile Reflux Scintigraphy (BRS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Upper Gastrointestinal Endoscopy (UGE)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bile Reflux Scintigraphy (BRS) and UGE findings
Number of subjects: 40
Study: 29072677

Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist (NAVA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Synchronized Intermittent Mandatory Ventilation with Pressure Controlled and Supported Breath (SIMV (PC) PS)
Number of subjects: 24
Study: 27578117

Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg weekly for 26 weeks
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Mipomersen in open-label extension (OLE) for 52 or 104 weeks
Number of subjects: 7
Study: 25394366

Group type: EXPERIMENTAL
Intervention: Parallel dual-site differential control
Number of subjects: 5

Group type: COMPARATOR
Intervention: Sequential pattern recognition control
Number of subjects: 5
Study: 23546562

Group type: EXPERIMENTAL
Intervention: Group incentive ($500 per month split among participants within groups of 5 who met or exceeded weight-loss goals)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Group incentive
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control (24 weeks of monthly weigh-ins)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Individual incentive ($100 per person per month for meeting or exceeding weight-loss goals)
Number of subjects: 105
Study: 20951487

Group type: EXPERIMENTAL
Intervention: Cinacalcet plus low-dose activated vitamin D analogues (Cinacalcet-D)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin D analogues alone (Flex-D)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cinacalcet plus vitamin D analogues (Cinacalcet-D)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Switching to generic calcitriol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Switching sevelamer to lanthanum
Number of subjects: 0
Study: 18562104

Group type: EXPERIMENTAL
Intervention: Naltrexone (50mg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 16860459

Group type: EXPERIMENTAL
Intervention: Conventional video-laparoscopy pelvic trainer
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cardboard box with a cut-out top
Number of subjects: 36
Study: 12000492

Group type: EXPERIMENTAL
Intervention: Pragmatic 'real world' randomized trials
Number of subjects: 0
Study: 9658990

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 7543713

Group type: EXPERIMENTAL
Intervention: Low-dose heparin (5000 units 2 hours before operation and 5000 units every 8 hours for 5 days after operation)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Dextran 40 (administered during the operation with an additional infusion of 500 ml/day for the next 3 days)
Number of subjects: 89
Study: 2795401

Group type: EXPERIMENTAL
Intervention: Parent present during injection
Number of subjects: 47

Group type: COMPARATOR
Intervention: Parent absent during injection
Number of subjects: 47
Study: 338206

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 30591338

Group type: EXPERIMENTAL
Intervention: STI‐12 starter culture
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: RST‐743 starter culture
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: R‐707 starter culture
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: XPL‐2 starter culture
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: CHN‐22 starter culture
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Consumer preferences
Number of subjects: 5
Study: 30549494

Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate (HD)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP)
Number of subjects: 311
Study: 26769482

Group type: EXPERIMENTAL
Intervention: Pulmojet
Number of subjects: 421

Group type: COMPARATOR
Intervention: Diskus
Number of subjects: 421

Group type: COMPARATOR
Intervention: Turbohaler
Number of subjects: 421
Study: 24740662

Group type: EXPERIMENTAL
Intervention: High-dosage tamoxifen (80 mg/day) administered from six weeks prior until twelve weeks after surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22147649

Group type: EXPERIMENTAL
Intervention: MDX-1100 (10 mg/kg every other week)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 19079815

Group type: EXPERIMENTAL
Intervention: Olanzapine/fluoxetine combination (OFC)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Lamotrigine (Lam)
Number of subjects: 205
Study: 17979011

Group type: EXPERIMENTAL
Intervention: Intensive physiotherapy programme (3-day programme with 7 specific exercises, lasting approximately one hour)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual care (mainly consisting of walking)
Number of subjects: 58
Study: 16334120

Group type: EXPERIMENTAL
Intervention: Weekly 1‐h or 3‐h infusions of paclitaxel
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: T(>0.05) > or = 20.7 hours
Number of subjects: 21
Study: 11986448

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension, 0.5 mg daily (n = 168)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Cromolyn sodium nebulizer solution, 20 mg 4 times daily (n = 167)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension
Number of subjects: 335
Study: 9535299

Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Minimal therapy (control)
Number of subjects: 23
Study: 7893023

Group type: EXPERIMENTAL
Intervention: neostigmine 70 micrograms/kg + glycopyrrolate 10 micrograms/kg, i.v.
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: edrophonium 1 mg/kg + atropine 10 micrograms/kg, i.v.
Number of subjects: 113

Group type: COMPARATOR
Intervention: saline
Number of subjects: 113
Study: 2798577

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 328210

Group type: EXPERIMENTAL
Intervention: 30 mg propantheline
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 31072180

Group type: EXPERIMENTAL
Intervention: Montelukast plus methylprednisolone
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 74
Study: 27576860

Group type: EXPERIMENTAL
Intervention: CLT-28643 (single subconjunctival injection intraoperatively) followed by postoperative vehicle eye drops (CLT+ group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CLT-28643 (single subconjunctival injection intraoperatively) followed by CLT-28643 eye drops 4 times daily (CLT++ group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) (0.04%, sponge application, 2 min) followed by vehicle eye drops postoperatively (MMC group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control-surgery group (no adjunctive therapy)
Number of subjects: 24
Study: 26293513

Group type: EXPERIMENTAL
Intervention: Tapentadol IR 50 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tapentadol IR 75 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tapentadol IR (50 and 75 mg)
Number of subjects: 60
Study: 23320451

Group type: EXPERIMENTAL
Intervention: Octaplas LG plasma product
Number of subjects: 60

Group type: COMPARATOR
Intervention: Octaplas S/D plasma product
Number of subjects: 60
Study: 21928240

Group type: EXPERIMENTAL
Intervention: Brachial plexus block (BPB) with 15 mL ropivacaine 1% and 10 mL saline via axillary approach
Number of subjects: 40

Group type: COMPARATOR
Intervention: Local anesthesia with lidocaine 2%
Number of subjects: 40
Study: 19550413

Group type: EXPERIMENTAL
Intervention: Early-precut group (n=77)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Late-access group (n=74)
Number of subjects: 151
Study: 17463075

Group type: EXPERIMENTAL
Intervention: TENS application for 60 minutes daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: TENS application for 8 hours daily
Number of subjects: 32
Study: 15465747

Group type: EXPERIMENTAL
Intervention: Plasma selenium levels
Number of subjects: 949
Study: 11885210

Group type: EXPERIMENTAL
Intervention: Experimental group (n = 68)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 93
Study: 9551703

Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg on day 1 and 200 mg on days 2-4)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 1760050

Group type: EXPERIMENTAL
Intervention: Regular lager (4.2%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-alcohol lager
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-alcohol lager
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topping-up with non-alcohol lager
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topping-up with low-alcohol lager
Number of subjects: 0
Study: 7059257

Group type: EXPERIMENTAL
Intervention: Patient education program focusing on pill taking, appointment keeping, and dietary sodium reduction
Number of subjects: 39

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 39
Study: 30789492

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM)
Number of subjects: 636

Group type: COMPARATOR
Intervention: Control (postoperative analgesics only)
Number of subjects: 636
Study: 28583301

Group type: EXPERIMENTAL
Intervention: Multi-component quality improvement (QI) strategy including support of hospital leadership, use of order sets, audit and feedback, and active pharmacy involvement
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Multi-component quality improvement (QI) strategy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control groups (not specified intervention)
Number of subjects: 8
Study: 26902700

Group type: EXPERIMENTAL
Intervention: Tribulus Terrestris
Number of subjects: 60
Study: 24509134

Group type: EXPERIMENTAL
Intervention: Anatabine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 17
Study: 22424002

Group type: EXPERIMENTAL
Intervention: CCTA as the first diagnostic test following serial biomarkers
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard of care (no testing or functional testing such as exercise ECG, stress radionuclide imaging, or stress echocardiography)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1000
Study: 20378381

Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Caliper (CLP) measurements
Number of subjects: 207

Group type: COMPARATOR
Intervention: Circumference (CF) measurements
Number of subjects: 207
Study: 18728907

Group type: EXPERIMENTAL
Intervention: 2.5 hours of weekly, mandatory physical exercise of middle-to-high intensity
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Reduction of full-time weekly workhours from 40 to 37.5 hours
Number of subjects: 177

Group type: COMPARATOR
Intervention: Reference group
Number of subjects: 177
Study: 15903382

Group type: EXPERIMENTAL
Intervention: Training group (n = 52) participated in 2 field-training sessions per week.
Number of subjects: 68

Group type: COMPARATOR
Intervention: Nonexercise control group (n = 16).
Number of subjects: 68
Study: 12566015

Group type: EXPERIMENTAL
Intervention: Timolol 0.5%/dorzolamide 2% fixed combination
Number of subjects: 32

Group type: COMPARATOR
Intervention: Timolol maleate 0.5% and unoprostone 0.15%
Number of subjects: 32
Study: 10234600

Group type: COMPARATOR
Intervention: Argatroban 1 microgram/kg/min infused alone for 5 hours (regimen A)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Argatroban 1 microgram/kg/min infused on day 6 of a 7-day oral regimen of 500 mg erythromycin four times daily (regimen B)
Number of subjects: 14
Study: 9193325

Group type: EXPERIMENTAL
Intervention: Clodronate 1,600 mg/d
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (no clodronate)
Number of subjects: 148
Study: 1534993

Group type: EXPERIMENTAL
Intervention: 3 micrograms/ml sufentanil in saline (Group S)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 1.5 micrograms/ml sufentanil in 0.125% bupivacaine (Group SB)
Number of subjects: 73

Group type: COMPARATOR
Intervention: 0.25% bupivacaine (Group B)
Number of subjects: 73
Study: 3456271

Group type: EXPERIMENTAL
Intervention: Doxorubicin (75 mg/m2 iv every 3 weeks)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Epirubicin (75 mg/m2 iv every 3 weeks)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 42
Study: 31409671

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 210
Study: 30005094

Group type: EXPERIMENTAL
Intervention: Lidocaine 4% and Benzocaine 20%
Number of subjects: 14

Group type: COMPARATOR
Intervention: Compounded Lidocaine 23%/Tetracaine 7% (23/7)
Number of subjects: 14
Study: 27235515

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 24284272

Group type: EXPERIMENTAL
Intervention: Kinesio Tape (KT)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Placebo (P)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 99
Study: 22401811

Group type: EXPERIMENTAL
Intervention: Vitrification with cumulus cells (Group A)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Vitrification without cumulus cells (Group B)
Number of subjects: 46
Study: 20810892

Group type: EXPERIMENTAL
Intervention: Delayed-response tasks with motor planning (desired goals)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delayed-response tasks with motor planning (undesired goals)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Memory/attention-only conditions
Number of subjects: 0
Study: 17630262

Group type: EXPERIMENTAL
Intervention: Group affirmation (affirming an important group value)
Number of subjects: 0
Study: 15662234

Group type: EXPERIMENTAL
Intervention: Low-dose controlled-release nifedipine (20 mg/day) plus candesartan (8 mg/day) combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Up-titrated candesartan (12 mg/day) monotherapy
Number of subjects: 0
Study: 12693152

Group type: EXPERIMENTAL
Intervention: Intramuscular HBV vaccine (20 micrograms each dose) at 0, 1, and 6 month intervals
Number of subjects: 96

Group type: COMPARATOR
Intervention: Intradermal HBV vaccine (2 micrograms each dose) at 0, 1, and 6 month intervals
Number of subjects: 96
Study: 10090959

Group type: EXPERIMENTAL
Intervention: Invaginating stripping of the LSV
Number of subjects: 30

Group type: COMPARATOR
Intervention: Classic stripping of the LSV
Number of subjects: 30
Study: 8771155

Group type: EXPERIMENTAL
Intervention: PCR assay for detecting rearranged Ig heavy chain genes
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: PCR assay
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: PCR analysis of B-cell lymphoproliferative disease
Number of subjects: 140
Study: 1835292

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (0.036 mg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Albuterol (0.18 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 7333755

Group type: EXPERIMENTAL
Intervention: Sitting position at rest
Number of subjects: 12

Group type: COMPARATOR
Intervention: Supine position at rest
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sitting position during dynamic exercise
Number of subjects: 12

Group type: COMPARATOR
Intervention: Supine position during dynamic exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sitting position and Supine position
Number of subjects: 12
Study: 31377160

Group type: EXPERIMENTAL
Intervention: Hormone Therapy (HT) alone
Number of subjects: 2995

Group type: COMPARATOR
Intervention: Radiation Therapy (RT) alone
Number of subjects: 2995
Study: 28647759

Group type: EXPERIMENTAL
Intervention: Mom Power parenting intervention
Number of subjects: 122

Group type: COMPARATOR
Intervention: Weekly mailings of parenting information (control)
Number of subjects: 122
Study: 25556985

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 23095006

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention program (exercise, diet, and hot bathing) - Group A
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Exercise and diet intervention - Group B
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Hot bathing intervention - Group C
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group - Group D
Number of subjects: 66
Study: 21343393

Group type: EXPERIMENTAL
Intervention: Poly (A:U) dsRNA
Number of subjects: 194
Study: 20209742

Group type: EXPERIMENTAL
Intervention: Hepatitis B ESL educational curriculum
Number of subjects: 325

Group type: COMPARATOR
Intervention: Control group (standard ESL education without hepatitis B curriculum)
Number of subjects: 325
Study: 18552044

Group type: EXPERIMENTAL
Intervention: 10 mg/day cetirizine
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 5 mg/day levocetirizine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 15472793

Group type: EXPERIMENTAL
Intervention: Continued PI-based therapy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Stavudine usage
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control of viral replication
Number of subjects: 45

Group type: COMPARATOR
Intervention: Lipid and glycemic parameters
Number of subjects: 45
Study: 11486240

Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg/day
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg/day
Number of subjects: 67

Group type: COMPARATOR
Intervention: Amlodipine 5 mg/day
Number of subjects: 67

Group type: COMPARATOR
Intervention: Amlodipine 10 mg/day
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 67
Study: 9568453

Group type: EXPERIMENTAL
Intervention: Enalapril 2.5 mg twice daily
Number of subjects: 1532

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg twice daily
Number of subjects: 1532

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg twice daily
Number of subjects: 1532